ST段抬高型心肌梗死治疗的最新进展
Recent Advances in the Treatment of ST-Segment Elevation Myocardial Infarction.
作者信息
Hong Mun K
机构信息
Cardiac Catheterization Laboratory and Interventional Cardiology, St. Luke's-Roosevelt Hospital Center, 1111 Amsterdam Avenue, New York, NY 10025, USA ; Columbia University College of Physicians and Surgeons, 630 W. 168th St., New York, NY 10032, USA.
出版信息
Scientifica (Cairo). 2012;2012:683683. doi: 10.6064/2012/683683. Epub 2012 Sep 16.
Abstract
ST-segment elevation myocardial infarction (STEMI) represents the most urgent condition for patients with coronary artery disease. Prompt diagnosis and therapy, mainly with primary angioplasty using stents, are important in improving not only acute survival but also long-term prognosis. Recent advances in angioplasty devices, including manual aspiration catheters and drug-eluting stents, and pharmacologic therapy, such as potent antiplatelet and anticoagulant agents, have significantly enhanced the acute outcome for these patients. Continuing efforts to educate the public and to decrease the door-to-balloon time are essential to further improve the outcome for these high-risk patients. Future research to normalize the left ventricular function by autologous stem cell therapy may also contribute to the quality of life and longevity of the patients surviving STEMI.
摘要
ST段抬高型心肌梗死（STEMI）是冠心病患者最紧急的情况。及时诊断和治疗，主要是使用支架进行直接血管成形术，对于不仅改善急性生存率而且改善长期预后都很重要。血管成形术设备的最新进展，包括手动抽吸导管和药物洗脱支架，以及药物治疗，如强效抗血小板和抗凝剂，显著改善了这些患者的急性治疗效果。持续努力对公众进行教育并缩短门球时间对于进一步改善这些高危患者的治疗效果至关重要。通过自体干细胞疗法使左心室功能正常化的未来研究也可能有助于STEMI存活患者的生活质量和寿命。
相似文献
1
Recent Advances in the Treatment of ST-Segment Elevation Myocardial Infarction.
Scientifica (Cairo). 2012;2012:683683. doi: 10.6064/2012/683683. Epub 2012 Sep 16.
2
5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial.
JACC Cardiovasc Interv. 2011 Jan;4(1):24-9. doi: 10.1016/j.jcin.2010.11.003.
3
Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial.
Circulation. 2009 Sep 15;120(11):964-72. doi: 10.1161/CIRCULATIONAHA.108.830372. Epub 2009 Aug 31.
4
[Evidence-based management of ST-segment elevation myocardial infarction (STEMI). Latest guidelines of the European Society of Cardiology (ESC) 2010].
Herz. 2010 Dec;35(8):558-64. doi: 10.1007/s00059-010-3401-8.
5
Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial.
JACC Cardiovasc Interv. 2014 Aug;7(8):849-56. doi: 10.1016/j.jcin.2014.02.016.
6
Impact of diabetes on the benefits from everolimus-eluting stent as compared to first-generation drug-eluting stent in patients with ST elevation myocardial infarction.
Diab Vasc Dis Res. 2015 Sep;12(5):306-14. doi: 10.1177/1479164115592252. Epub 2015 Jul 6.
7
Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
JACC Cardiovasc Interv. 2015 Jan;8(1 Pt B):189-197. doi: 10.1016/j.jcin.2014.10.005.
8
Routine stenting vs. balloon angioplasty in ST-segment elevation myocardial infarction due to proximal left anterior descending coronary artery occlusion.
J Cardiovasc Med (Hagerstown). 2009 Jan;10(1):22-6. doi: 10.2459/JCM.0b013e32830a48d2.
9
API expert consensus document on management of ischemic heart disease.
J Assoc Physicians India. 2006 Jun;54:469-80.
10
Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials.
JACC Cardiovasc Interv. 2014 Jan;7(1):55-63. doi: 10.1016/j.jcin.2013.07.012. Epub 2013 Dec 11.
引用本文的文献
1
Knowledge, attitudes and beliefs about acute coronary syndrome among patients diagnosed with acute coronary syndrome, Addis Ababa, Ethiopia.
BMC Cardiovasc Disord. 2022 Oct 14;22(1):444. doi: 10.1186/s12872-022-02893-2.
2
Associations of changes in patient characteristics and management with decrease in mortality rates of men and women with ST-elevation myocardial infarction - a propensity score-matched analysis.
Arch Med Sci. 2020 Mar 10;16(4):772-780. doi: 10.5114/aoms.2020.93458. eCollection 2020.
3
Survival benefit from recent changes in management of men and women with ST-segment elevation myocardial infarction treated with percutaneous coronary interventions.
Cardiol J. 2019;26(5):459-468. doi: 10.5603/CJ.a2018.0057. Epub 2018 Jun 20.
4
The effects of fibrinolytic before referring STEMI patients: A systematic review and meta-analysis.
Int J Cardiol Heart Vasc. 2017 Apr 8;15:9-14. doi: 10.1016/j.ijcha.2017.03.003. eCollection 2017 Jun.
本文引用的文献
1
Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial.
J Am Coll Cardiol. 2012 Jul 31;60(5):381-7. doi: 10.1016/j.jacc.2012.01.073.
2
An evidence-based review of current anti-platelet options for STEMI patients.
Int J Cardiol. 2013 Jun 20;166(2):294-303. doi: 10.1016/j.ijcard.2012.04.160. Epub 2012 Jun 17.
3
Enhanced endothelialization of a new stent polymer through surface enhancement and incorporation of growth factor-delivering microparticles.
J Cardiovasc Transl Res. 2012 Aug;5(4):519-27. doi: 10.1007/s12265-012-9381-8. Epub 2012 May 26.
4
The patient's interpretation of myocardial infarction symptoms and its role in the decision process to seek treatment: the MONICA/KORA Myocardial Infarction Registry.
Clin Res Cardiol. 2012 Nov;101(11):909-16. doi: 10.1007/s00392-012-0475-8. Epub 2012 May 23.
5
Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial.
J Am Coll Cardiol. 2012 May 15;59(20):1752-9. doi: 10.1016/j.jacc.2011.12.042.
6
Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials.
Arch Intern Med. 2012 Apr 23;172(8):611-21; discussion 621-2. doi: 10.1001/archinternmed.2012.758.
7
Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: results from long-term follow-up of the Occluded Artery Trial (OAT) cohort.
Am Heart J. 2012 Apr;163(4):563-71. doi: 10.1016/j.ahj.2012.01.016.
8
Target Temperature Management after out-of-hospital cardiac arrest--a randomized, parallel-group, assessor-blinded clinical trial--rationale and design.
Am Heart J. 2012 Apr;163(4):541-8. doi: 10.1016/j.ahj.2012.01.013.
9
Long-Term (>10 Years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents.
Circulation. 2012 May 15;125(19):2343-53. doi: 10.1161/CIRCULATIONAHA.110.000901. Epub 2012 Apr 16.
10
Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials.
Atherosclerosis. 2012 Jun;222(2):426-33. doi: 10.1016/j.atherosclerosis.2012.02.041. Epub 2012 Mar 7.
Zotero 插件